Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Sells 1,500 Shares
SEC Form 4 Filing
Bruce C Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc, sold 1,500 ordinary shares on January 2, 2025, at a price of $123.43 per share.
Summary
- Bruce C Cozadd, the Chairman and CEO of Jazz Pharmaceuticals plc, sold 1,500 ordinary shares of the company on January 2, 2025.
- The sale was executed at a price of $123.43 per share.
- Following the transaction, Cozadd directly owns 425,525 ordinary shares.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine transaction under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.
Industry Context
Insider sales are a common occurrence and are often scrutinized by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales under a 10b5-1 plan are less likely to be indicative of management sentiment, as these plans are pre-arranged.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Bruce C Cozadd sold 1,500 ordinary shares. |
| 01/03/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.